Non-lysosomal glucosylceramidase


  • Accession: Q69ZF3
  • Swissprot: GBA2_MOUSE
  • Organism: Mus musculus
  • Gene: Gba2
  • Target class: Enzyme

Drug Relations:

Miglustat functions as a competitive and reversible inhibitor of the enzyme glucosylceramide synthase, the initial enzyme in a series of reactions which results in the synthesis of most glycosphingolipids. Miglustat helps reduce the rate of glycosphingolipid biosynthesis so that the amount of glycosphingolipid substrate is reduced to a level which allows the residual activity of the deficient glucocerebrosidase enzyme to be more effective (substrate reduction therapy). In vitro and in vivo studies have shown that miglustat can reduce the synthesis of glucosylceramide-based glycosphingolipids. Bioactivity details MOA